Factor VIII products and inhibitor development in severe hemophilia A
| Autor: | Gouw, S.C., Bom, J.G. van der, Ljung, R., Escuriola, C., Cid, A.R., Claeyssens-Donadel, S., Geet, C. van, Kenet, G., Makipernaa, A., Molinari, A.C., Muntean, W., Kobelt, R., Rivard, G., Santagostino, E., Thomas, A., Berg, H.M. van den, PedNet RODIN Study Grp |
|---|---|
| Přispěvatelé: | AII - Amsterdam institute for Infection and Immunity, Paediatric Infectious Diseases / Rheumatology / Immunology |
| Jazyk: | angličtina |
| Rok vydání: | 2013 |
| Předmět: |
Male
medicine.medical_specialty 030204 cardiovascular system & hematology Hemophilia A Bethesda unit Gastroenterology Antibodies 03 medical and health sciences 0302 clinical medicine Von Willebrand factor In vivo Internal medicine von Willebrand Factor medicine Humans Cumulative incidence Child Factor VIII Hematology biology business.industry Liter General Medicine 3. Good health Titer Immunology biology.protein Antibody business 030215 immunology |
| Zdroj: | New England journal of medicine, 368(3), 231-239. Massachussetts Medical Society |
| ISSN: | 0028-4793 |
| Popis: | For previously untreated children with severe hemophilia A, it is unclear whether the type of factor VIII product administered and switching among products are associated with the development of clinically relevant inhibitory antibodies (inhibitor development). We evaluated 574 consecutive patients with severe hemophilia A (factor VIII activity |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|